Atlas Venture Life Science Advisors, LLC Q3 2023 Filing

Filed November 13, 2023

Portfolio Value

$645.6B

Holdings

15

Report Date

Q3 2023

Filing Type

13F-HR

All Holdings (15 positions)

#StockSharesValue% PortfolioType
1
IRONDisc Medicine, Inc.
2,745,335$129.0B19.98%
2
DAWNDay One Biopharmaceuticals, Inc.
7,608,394$93.4B14.46%
3
DYNDyne Therapeutics, Inc.
9,885,449$88.6B13.72%
4
KYMRKymera Therapeutics, Inc.
5,858,262$81.4B12.61%
5
THRDThird Harmonic Bio, Inc.
10,907,859$69.7B10.80%
6
REPLReplimune Group, Inc.
2,098,300$35.9B5.56%
7
VIGLVigil Neuroscience, Inc.
5,836,874$31.5B4.87%
8
GBIOGBXGeneration Bio, Co.
8,279,484$31.4B4.86%
9
AVTEAerovate Therapeutics, Inc.
2,039,249$27.7B4.29%
10
Ikena Oncology, Inc.
5,018,178$21.7B3.37%
11
AKROAkero Therapeutics, Inc.
359,251$18.2B2.81%
12
AvroBio, Inc.
4,541,381$7.0B1.08%
13
XLOXilio Therapeutics, Inc.
2,759,344$5.8B0.90%
14
DNTHDianthus Therapeutics, Inc.
236,979$3.2B0.50%
15
SPROSpero Therapeutics, Inc.
1,013,438$1.2B0.19%